Published in Oncotarget on October 30, 2014
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
Characterization of the murine myeloid precursor cell line MuMac-E8. PLoS One (2014) 1.39
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids (2016) 0.89
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget (2015) 0.88
Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85
A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget (2015) 0.75
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. Oncoimmunology (2015) 0.75
Suppression of mRNA Nanoparticle Transfection in Human Fibroblasts by Selected Interferon Inhibiting Small Molecule Compounds. Biomolecules (2017) 0.75
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008) 2.76
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med (2000) 2.69
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 1.89
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol (2004) 1.87
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res (2009) 1.86
Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov (2014) 1.80
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer (2011) 1.73
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell (2014) 1.31
Signaling defects in anti-tumor T cells. Immunol Rev (2008) 1.28
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med (2011) 1.27
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res (2012) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Turning tumors into vaccines: co-opting the innate immune system. Immunity (2013) 0.99
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer (2013) 0.97
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther (2014) 0.93
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget (2014) 0.92
Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther (2002) 0.92
In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther (2011) 0.89
The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines (2014) 0.88
Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol (2011) 0.88
Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int (2013) 0.86
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. J Clin Cell Immunol (2012) 0.85
Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med (2013) 0.82
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82
FIST, a sword and shield fusokine for cancer immunotherapy. Oncoimmunology (2012) 0.80
Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J Leukoc Biol (2005) 0.80
Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res (2001) 0.77
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids (2016) 0.89
The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome. Eur J Immunol (2015) 0.76
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids (2016) 0.75